Skip to content

Outlook Therapeutics, Inc.

OTLK· NasdaqCore metricsCIK 1649989

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -8.77%
Market cap
$107.14M
243.45M shares
Filings
834
$1.41M
FY 2025−82.6% FY25 yoy
-$20.32M
Q3 2026N/M FY25 yoy
-$10.81M
Q3 2026N/M FY25 yoy
-$32.73M
FY 2019derivedN/M FY19 yoy
-$0.15
Q3 2026N/M FY25 yoy
$11.24M
Q3 2026−45.9% FY25 yoy
$107.14M
—
75.8×
—
—
—

FY2025 figures · derived

Price

$0.440164.51%$0.7999past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$1.41MFY 2025
$8.15M0FY 2015FY 2016FY 2017FY 2018FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-09-30$1,413,535reported
FY 20192019-09-30$8,146,123reported
FY 20182018-09-30$3,087,560reported
FY 20172017-09-30$3,811,519reported
FY 20162016-09-30$2,979,576reported
FY 20152015-09-30$5,219,237reported

Biological products, except diagnostic substances

Outlook Therapeutics, Inc. is the 76th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Outlook Therapeutics, Inc. · CIK 1649989 · Engraved from SEC EDGAR